Abdullah also attributed GSK’s willingness to go all-in on mo-rez on the leadership of Luke Miels, who stepped up as CEO of ...

Boehringer Ingelheim and Click Therapeutics are restructuring their marketing deal for the software-based schizophrenia ...

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...

The second time is not the charm for Replimune’s melanoma candidate RP1. | The second time is not the charm for Replimune’s ...

AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI ...

Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise ...

A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...

Artificial intelligence has long been seen as a way to supercharge drug development. | Artificial intelligence has long been seen as a way to supercharge drug development. But a whole new frontier of ...

Oricell Therapeutics has now raised over $110 million in its final funding round before the Chinese CAR-T therapy biotech ...

Roche has joined its Big Pharma peers in the emerging degrader-antibody conjugate (DAC) space, paying C4 Therapeutics $20 ...

Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune ...

After entering 2026 hungry for deals, Gilead Sciences has wasted no time eating its fill. | After entering 2026 hungry for ...